Similar companies
Income Statement (USD)
Q2 '24 | QoQ | |
---|---|---|
Revenue | 14M | 4.7% |
Gross Profit | -32M | 2.5% |
Cost of Revenue | 46M | 0.4% |
Operating expense | 111M | 8% |
Net Income | -98M | 6.7% |
EBITDA | -96M | 7.8% |
Balance Sheet (USD)
Q2 '24 | QoQ | |
---|---|---|
Total Assets | 776M | 39.1% |
Total Liabilities | 191M | 22.2% |
Total Equity | 584M | 45.7% |
Shares Outstanding | 281M | 18.3% |
Cash Flow (USD)
Q2 '24 | QoQ | |
---|---|---|
Cash from operations | -82M | 19.6% |
Cash from investing | -4.2M | 37.1% |
Cash from financing | 263M | 1793.4% |
EPS
Financial Highlights for Recursion Pharmaceuticals in Q2 '24
Recursion Pharmaceuticals reported a revenue of 14M, which is a 4.7% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at -32M, marking a 2.5% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 46M, a -0.4% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 111M, showing a 8% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -98M, showing a -6.7% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -96M, showing a -7.8% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Recursion Pharmaceuticals faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies. A decline in EBITDA signals potential operational challenges or increased costs.